323 related articles for article (PubMed ID: 25432858)
1. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?
Cornier MA; Eckel RH
Curr Atheroscler Rep; 2015; 17(2):475. PubMed ID: 25432858
[TBL] [Abstract][Full Text] [Related]
2. [Myopathies under therapy with lipid-lowering agents].
Köller H; Neuhaus O; Schroeter M; Hartung HP
Nervenarzt; 2005 Feb; 76(2):212-7. PubMed ID: 15609055
[TBL] [Abstract][Full Text] [Related]
3. Statin-associated myopathy.
Thompson PD; Clarkson P; Karas RH
JAMA; 2003 Apr; 289(13):1681-90. PubMed ID: 12672737
[TBL] [Abstract][Full Text] [Related]
4. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity.
Gillett RC; Norrell A
Am Fam Physician; 2011 Mar; 83(6):711-6. PubMed ID: 21404982
[TBL] [Abstract][Full Text] [Related]
5. Statin induced myopathy.
Frank RE
J Insur Med; 2009; 41(2):132-5. PubMed ID: 19845216
[TBL] [Abstract][Full Text] [Related]
6. [Statin intolerance].
Graversen CB; Larsen ML; Schmidt EB
Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
[TBL] [Abstract][Full Text] [Related]
7. Statin intolerance: now a solved problem.
Sikka P; Kapoor S; Bindra VK; Sharma M; Vishwakarma P; Saxena KK
J Postgrad Med; 2011; 57(4):321-8. PubMed ID: 22120862
[TBL] [Abstract][Full Text] [Related]
8. Managing statin-induced muscle toxicity in a lipid clinic.
Blaier O; Lishner M; Elis A
J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
[TBL] [Abstract][Full Text] [Related]
9. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
Harper CR; Jacobson TA
Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856
[TBL] [Abstract][Full Text] [Related]
10. Overcoming toxicity and side-effects of lipid-lowering therapies.
Wilkinson MJ; Laffin LJ; Davidson MH
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):439-52. PubMed ID: 24840269
[TBL] [Abstract][Full Text] [Related]
11. Statin safety: lessons from new drug applications for marketed statins.
Jacobson TA
Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
[TBL] [Abstract][Full Text] [Related]
12. Strategies to overcome statin intolerance.
Agouridis AP; Nair DR; Mikhailidis DP
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
[TBL] [Abstract][Full Text] [Related]
13. Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M
Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999
[TBL] [Abstract][Full Text] [Related]
14. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.
Keating AJ; Campbell KB; Guyton JR
Ann Pharmacother; 2013 Mar; 47(3):398-404. PubMed ID: 23482733
[TBL] [Abstract][Full Text] [Related]
15. Statin-Associated Myalgias and Muscle Injury-Recognizing and Managing Both While Still Lowering the Low-Density Lipoprotein.
Mammen AL
Rheum Dis Clin North Am; 2022 May; 48(2):445-454. PubMed ID: 35400370
[TBL] [Abstract][Full Text] [Related]
16. Expert opinion: the therapeutic challenges faced by statin intolerance.
Patel J; Martin SS; Banach M
Expert Opin Pharmacother; 2016 Aug; 17(11):1497-507. PubMed ID: 27254275
[TBL] [Abstract][Full Text] [Related]
17. Statin intolerance.
Ahmad Z
Am J Cardiol; 2014 May; 113(10):1765-71. PubMed ID: 24792743
[TBL] [Abstract][Full Text] [Related]
18. Is there value in liver function test and creatine phosphokinase monitoring with statin use?
Sniderman AD
Am J Cardiol; 2004 Nov; 94(9A):30F-34F. PubMed ID: 15519289
[TBL] [Abstract][Full Text] [Related]
19. Statin-induced apoptosis and skeletal myopathy.
Dirks AJ; Jones KM
Am J Physiol Cell Physiol; 2006 Dec; 291(6):C1208-12. PubMed ID: 16885396
[TBL] [Abstract][Full Text] [Related]
20. Managing the underestimated risk of statin-associated myopathy.
Rallidis LS; Fountoulaki K; Anastasiou-Nana M
Int J Cardiol; 2012 Sep; 159(3):169-76. PubMed ID: 21813193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
